Initial phase II results of Arzerra in DLBCL released

large bcell lymphoma peripheral.jpeg

Results have been announced from a phase II study of Arzerra (ofatumamab) in the treatment of diffuse large B-cell lymphoma (DLBCL). 81 patients were involved in the single-arm study, the majority of them heavily pre-treated by rituximab or a stem cell transplant.

The study's primary endpoint was overall response rate (ORR), which was observed to be just 11% after a median of 6,9 months. These kinds of results will make it difficult for the manufacturer to get it approved for DLBCL.

The FDA initially approved Arzerra (ofatumamab) in November 2009 under its accelerated approval process for relapsed or refractory chronic lymphocytic leukemia.

HEMATOLOGICAL CANCER TYPE(S)

Diffuse large B-cell lymphoma (DLBCL)

WHERE WAS THIS RESEARCH PUBLISHED?

The data has not yet been published.

By Ross Bonander

Source

MarketWatch.com

LymphomaInfo Social